E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
High Grade Uterine Sarcoma (HGUtS) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10046821 |
E.1.2 | Term | Uterine sarcoma NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the trial is to assess, in High Grade Undifferentiated Uterine Sarcoma (HGUS), High Grade Endometrial Stromal Sarcoma (HGESS), High Grade Leiomyosarcomas (HGLMS) and High Grade (HG) adenosarcoma the activity (PFS at 4 months) of maintenance treatment with cabozantinib when compared with placebo after clinical benefit (CR, PR and SD) from standard chemotherapy (doxorubicin +/- ifosfamide) (given as an adjuvant treatment after curative surgery, or for locally advanced or metastatic disease). |
|
E.2.2 | Secondary objectives of the trial |
♦ To assess the efficacy of maintenance treatment with cabozantinib when compared with placebo, using progression-free survival, overall survival, response rate, and duration of response among patients with measurable disease. ♦ To describe the safety profile of cabozantinib in patients with HGUS, HGESS, HGLMS and HG adenosarcoma ♦ To explore the response rate to chemotherapy in first line treatment for patients with measurable disease |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) At registration: Patients can be registered no earlier than 4 weeks prior to start of the 1st line treatment and no later than 4 weeks after last administration of 1st line treatment. - Patients who are suitable for treatment with doxorubicin +/- ifosfamide and fall within one of the following patient populations: ♦ HGUS, HGESS, HGLMS and HG adenosarcoma ♦ FIGO stage II and stage III : if adjuvant chemotherapy is proposed ♦ FIGO stage IV: if first line chemotherapy is proposed - 1 formalin fixed paraffin embedded block of tumor tissue is sent after registration of a patient. Histological central review is mandatory to confirm histology and grade. - Patients must be at least 18 years old - Before patient registration, written informed consent for central collection of tissue block or slides and any other trial-specific procedures must be obtained
2) At Randomization Patients can be randomized within 12 weeks after last administration of 1st line treatment, before the start of protocol treatment - Central pathological confirmation: Histological evidence of HGUS, HGESS, HGLMS and HG adenosarcoma - Non-progressive patients (CR, PR, SD) after first line treatment and at time of randomization. - Patients able to swallow and retain oral tablets. - WHO/ECOG performance status 0-2 - Recovery to baseline or ≤ Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless AE(s) are clinically non significant and/or stable on supportive therapy - The subject has organ and marrow function and laboratory values as follows before randomization . Absolute neutrophil count (ANC) ≥ 1500/mm3 without colony stimulating factor support for 7 days . Platelets ≥ 100,000/mm3 . Hemoglobin ≥ 9 g/dL . Bilirubin ≤ 1.5 × the upper limit of normal. For subjects with known Gilbert’s disease, bilirubin ≤ 3.0 mg/dL . Serum albumin ≥ 2.8 g/dl . Serum creatinine ≤ 1.5 × the upper limit of normal or creatinine clearance (CrCl) ≥ 50 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72) × 0.85 . Alanine aminotransferase and aspartate aminotransferase ≤ 3.0 × the upper limit of normal or ≤ 5.0 x ULN if liver metastases . Lipase < 2.0 × the upper limit of normal and no radiologic or clinical evidence of pancreatitis . Urine Dipstick: If Urine Dipstick ≥ 2+, determine Urine Protein to Creatinine Ratio (UPCR) by quantitative analysis; if UPCR ≥ 1, then a 24-hour urine protein must be assessed. Any patient with protein > 150 mg over 24 hours would not be eligible. . Serum phosphorus, calcium, magnesium and potassium ≥ lower limit of normal . Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 × the upper limit of normal - Clinically normal cardiac function based on the institutional lower limit of normal (LVEF assessed by MUGA or ECHO), normal 12 lead ECG (no prolongation of corrected QT interval (QTc) > 500 msecs according to Fridericia's formula) and no history of any one or more of the following cardiovascular conditions within the past 6 months: . Cardiac angioplasty or stenting . Clinically-significant cardiac arrhythmias . Myocardial infarction . Unstable angina . Coronary artery bypass graft surgery . Symptomatic peripheral vascular disease . Class III or IV congestive heart failure, as defined by the New York Heart Association - Minor surgery within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study trt is permitted. - Women of child bearing potential must have a negative serum/urine pregnancy test within 3 days prior to the first dose of study treatment. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons. - Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 4 months after the last study treatment. - Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 8 weeks after the last study treatment. - Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial |
|
E.4 | Principal exclusion criteria |
At Registration ♦ The following tumor types are NOT eligible: low-grade ESS, leiomyosarcoma (low or intermediate), carcinosarcoma, low-grade adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and soft tissue PNET of uterus/cervix.
At randomization - Prior treatment with cabozantinib - history of congenital long QT syndrome - concurrent severe, clinically relevant hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment - patient with concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; - concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors - patients who have suffered a cerebrovascular accident at any time in the past, patients who have suffered a transient ischemic attack in the past 6 months, patients who have suffered a deep venous thrombosis or a pulmonary embolism in the past 6 months note: Patients with recent DVT who have been treated with therapeutic anti-coagulating agents and remained stable for at least 6 weeks are eligible: subjects with a venous filter are not eligible for this study - Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: - "known" intra-abdominal tumor/metastases invading GI mucosa - active peptic ulcer disease, - inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction. - malabsorption syndrome - Ongoing visceral complications from prior therapy - Prior gastrointestinal surgery ♦ Any of the following within 6 months before the first dose of study treatment: - abdominal or vaginal fistula - gastrointestinal perforation - bowel obstruction or gastric outlet obstruction - intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating study treatment even if the abscess occurred more than 6 months before the first dose of study treatment. - clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment - patients with evidence of tumor invading the GI tract or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of study treatment - patients with radiographic evidence of cavitating pulmonary lesion - patients with tumor in contact with, invading or encasing any major blood vessels. - patients evidence of tumor invading the GI tract, or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of study trt - evidence of active bleeding or bleeding diathesis. - hemoptysis ≥ 0.5 teaspoon of red blood within 3 months before the first dose of study treatment. Note: Any patient with a prior history of hemoptysis associated with metastatic disease must have a bronchoscopy to rule out endobronchial lesions. A patient with an endobronchial lesion - signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment - Major surgery or trauma within 12 weeks prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer. Complete wound healing from major surgery must have occurred one month before the first dose of study treatment. - clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment - Patients with clinically relevant ongoing complications from prior surgery . - concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4/5 - contraindications to cabozantinib - planned use of chemotherapy, radiation therapy, radionuclide treatment, small molecule TKI or hormonal therapy, and any other investigational agent during the treatment period. - poor oral hygiene or invasive dental or orofacial procedures within 28 days before the first dose of study treatment. Prior radiation therapy ♦ radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 42 weeks before the first dose of study treatment. Patient must have fully healed and there are no ongoing sequelae from the previous radiation therapy before the first dose of study treatment. ♦ systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. ♦ Patients with clinically relevant ongoing complications from prior radiation therapy - other malignancies within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death, treated with expected curative outcome |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression free survival rate |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at 4 months after randomization to cabozantinib or placebo |
|
E.5.2 | Secondary end point(s) |
1. Progression free survival rate 2. Overall survival 3. response rate and duration of response to cabozantinib 4. Response rate to doxorubicin-based chemotherapy after registration on trial for the patients with measurable disease 5. Quality of life (QoL) 6. Safety of cabozantinib in HGUS, HGESS, HGLMS and HG adenosarcoma |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1+2+3+4: prior to registration; prior to randomization; every 8 weeks during the first year of the maintenance period, then every 12 weeks; within 30 days after last dose (if no progression since randomization) 5. prior to registration; prior to randomization; within 3 days prior to each cycle, every 8 weeks during the first year of the maintenance period, then every 12 weeks; within 30 days after last dose 6. as of randomization, continuously per event up to 30 days after last dose; for patient who cross-over to cabozantinib after progression: every 4 weeks until further progression |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 27 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Belgium |
France |
Germany |
Italy |
Netherlands |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study occurs when all of the following criteria have been satisfied: -Thirty days after all patients have stopped protocol treatment. -The trial is mature for the analysis of the primary endpoint as defined in the protocol, ie. all randomized patients have adequate follow-up to determine their PFS status at 4 months. -The database has been fully cleaned and frozen for this analysis. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |